Nautilus Biotechnology Stock Analysis

NAUT Stock  USD 2.30  0.06  2.68%   
Nautilus Biotechnology is undervalued with Real Value of 2.95 and Target Price of 5.0. The main objective of Nautilus Biotechnology stock analysis is to determine its intrinsic value, which is an estimate of what Nautilus Biotechnology is worth, separate from its market price. There are two main types of Nautilus Biotechnology's stock analysis: fundamental analysis and technical analysis.
The Nautilus Biotechnology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Nautilus Biotechnology is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Nautilus Stock trading window is adjusted to America/New York timezone.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.

Nautilus Stock Analysis Notes

About 33.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.29. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nautilus Biotechnology recorded a loss per share of 0.56. The entity had not issued any dividends in recent years. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Nautilus Biotechnology contact Sujal Patel at 206 333 2001 or learn more at https://www.nautilus.bio.

Nautilus Biotechnology Investment Alerts

Nautilus Biotechnology generated a negative expected return over the last 90 days
Nautilus Biotechnology has high historical volatility and very poor performance
Net Loss for the year was (63.67 M) with profit before overhead, payroll, taxes, and interest of 0.
Nautilus Biotechnology currently holds about 299.34 M in cash with (51.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures
Roughly 33.0% of the company outstanding shares are owned by corporate insiders
Latest headline from finance.yahoo.com: 3 US Penny Stocks With Market Caps Up To 400M

Nautilus Biotechnology Upcoming and Recent Events

22nd of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Nautilus Largest EPS Surprises

Earnings surprises can significantly impact Nautilus Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-07-30
2024-06-30-0.16-0.140.0212 
2023-08-02
2023-06-30-0.15-0.130.0213 
2021-11-02
2021-09-30-0.1-0.12-0.0220 
View All Earnings Estimates

Nautilus Biotechnology Environmental, Social, and Governance (ESG) Scores

Nautilus Biotechnology's ESG score is a quantitative measure that evaluates Nautilus Biotechnology's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Nautilus Biotechnology's operations that may have significant financial implications and affect Nautilus Biotechnology's stock price as well as guide investors towards more socially responsible investments.

Nautilus Biotechnology Thematic Classifications

In addition to having Nautilus Biotechnology stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Measuring and Control Equipment Idea
Measuring and Control Equipment
USA Equities from Measuring and Control Equipment industry as classified by Fama & French

Nautilus Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Dimensional Fund Advisors, Inc.2024-09-30
692 K
Morgan Stanley - Brokerage Accounts2024-06-30
643.1 K
Clarius Group, Llc2024-09-30
636.5 K
Botty Investors Llc2024-09-30
614.3 K
Northern Trust Corp2024-09-30
507.5 K
Alyeska Investment Group, L.p.2024-09-30
441 K
Sentinel Trust Co Lba2024-09-30
315 K
Wexford Capital Lp2024-06-30
208.3 K
Hillman Co2024-09-30
200 K
Perceptive Advisors Llc2024-09-30
12.6 M
Cercano Management Llc2024-09-30
7.2 M
Note, although Nautilus Biotechnology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nautilus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 288.8 M.

Nautilus Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.20)
Return On Capital Employed(0.26)(0.27)
Return On Assets(0.21)(0.20)
Return On Equity(0.24)(0.23)

Management Efficiency

Nautilus Biotechnology has return on total asset (ROA) of (0.1762) % which means that it has lost $0.1762 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2804) %, meaning that it created substantial loss on money invested by shareholders. Nautilus Biotechnology's management efficiency ratios could be used to measure how well Nautilus Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. Total Current Liabilities is likely to drop to about 4.6 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 239 M in 2024
Last ReportedProjected for Next Year
Book Value Per Share 2.12  1.49 
Tangible Book Value Per Share 2.12  1.49 
Enterprise Value Over EBITDA(5.23)(5.49)
Price Book Value Ratio 1.41  2.12 
Enterprise Value Multiple(5.23)(5.49)
Price Fair Value 1.41  2.12 
Nautilus Biotechnology benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta
1.036
Return On Assets
(0.18)
Return On Equity
(0.28)

Technical Drivers

As of the 28th of November, Nautilus Biotechnology secures the Risk Adjusted Performance of (0.02), standard deviation of 3.89, and Mean Deviation of 3.05. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nautilus Biotechnology, as well as the relationship between them.

Nautilus Biotechnology Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Nautilus Biotechnology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Nautilus Biotechnology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Nautilus Biotechnology Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nautilus Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nautilus Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nautilus Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Subra Sankar few days ago
Acquisition by Subra Sankar of 140000 shares of Nautilus Biotechnology at 3.78 subject to Rule 16b-3
 
Sujal Patel over two weeks ago
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
 
Gwen Weld over two weeks ago
Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
 
Sujal Patel over a month ago
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
 
Mary Godwin over two months ago
Disposition of 47031 shares by Mary Godwin of Nautilus Biotechnology at 2.865 subject to Rule 16b-3
 
Sujal Patel over two months ago
Acquisition by Sujal Patel of 41654 shares of Nautilus Biotechnology at 2.9204 subject to Rule 16b-3
 
Kentaro Suzuki over two months ago
Insider Trading
 
Akinsanya Karen over three months ago
Acquisition by Akinsanya Karen of 14411 shares of Nautilus Biotechnology subject to Rule 16b-3
 
Posard Matthew L. over three months ago
Acquisition by Posard Matthew L. of 45000 shares of Nautilus Biotechnology at 2.56 subject to Rule 16b-3
 
Posard Matthew L. over three months ago
Acquisition by Posard Matthew L. of 45000 shares of Nautilus Biotechnology at 2.56 subject to Rule 16b-3
 
Mcilwain Matthew S over six months ago
Acquisition by Mcilwain Matthew S of 13568 shares of Nautilus Biotechnology at 7.6849 subject to Rule 16b-3
 
Subra Sankar over six months ago
Acquisition by Subra Sankar of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3

Nautilus Biotechnology Outstanding Bonds

Nautilus Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nautilus Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nautilus bonds can be classified according to their maturity, which is the date when Nautilus Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Nautilus Biotechnology Predictive Daily Indicators

Nautilus Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nautilus Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Nautilus Biotechnology Corporate Filings

F3
14th of November 2024
An amendment to the original Schedule 13D filing
ViewVerify
8K
29th of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
25th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
18th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
17th of September 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
8K
30th of July 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
17th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
13th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Nautilus Biotechnology Forecast Models

Nautilus Biotechnology's time-series forecasting models are one of many Nautilus Biotechnology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nautilus Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Nautilus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nautilus Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nautilus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nautilus Biotechnology. By using and applying Nautilus Stock analysis, traders can create a robust methodology for identifying Nautilus entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Nautilus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nautilus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nautilus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.0Buy5Odds
Nautilus Biotechnology current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Nautilus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Nautilus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Nautilus Biotechnology, talking to its executives and customers, or listening to Nautilus conference calls.
Nautilus Analyst Advice Details

Nautilus Stock Analysis Indicators

Nautilus Biotechnology stock analysis indicators help investors evaluate how Nautilus Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nautilus Biotechnology shares will generate the highest return on investment. By understating and applying Nautilus Biotechnology stock analysis, traders can identify Nautilus Biotechnology position entry and exit signals to maximize returns.
Begin Period Cash Flow115.5 M
Common Stock Shares Outstanding124.9 M
Total Stockholder Equity265.4 M
Property Plant And Equipment Net36.9 M
Cash And Short Term Investments173.4 M
Cash19.4 M
Accounts Payable1.6 M
Net Debt15.2 M
50 Day M A2.6801
Total Current Liabilities9.1 M
Other Operating Expenses76.2 M
Non Current Assets Total128.7 M
Non Currrent Assets Other1.2 M
Stock Based Compensation12.1 M

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.